
AI is about to change healthcare. These 37 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.
To own eToro, you really need to believe in its multi‑asset, social‑trading model scaling across more geographies and products, while staying on the right side of regulators. The recent move into New York’s crypto market adds a high‑profile proof point to that story, but, on its own, is unlikely to shift the near‑term earnings picture in a material way given the current size of US$13.7 billion in annual revenue. Where it does matter is on catalysts and risks: it reinforces eToro’s positioning as a regulated player in crypto at a time when revenue is expected to soften and earnings growth is slowing, and it slightly raises the company’s exposure to regulatory and crypto‑cycle volatility. With the stock trading well below consensus value and an ongoing buyback, execution in the US is now more central to the narrative.
However, tighter US oversight and crypto‑specific rules could still reshape eToro’s growth options in surprising ways. Despite retreating, eToro Group's shares might still be trading 34% above their fair value. Discover the potential downside here.Explore 21 other fair value estimates on eToro Group - why the stock might be worth less than half the current price!
Don't just follow the ticker - dig into the data and build a conviction that's truly your own.
Our top stock finds are flying under the radar-for now. Get in early:
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com